Vaccination strategies and transmission of COVID-19: evidence across leading countries

  title={Vaccination strategies and transmission of COVID-19: evidence across leading countries},
  author={Dongwoo Kim and Young Jun Lee},
  • Dongwoo Kim, Young Jun Lee
  • Published 14 September 2021
  • Economics
Vaccination has been perceived as a key to reaching “herd immunity” in the current COVID-19 pandemic. This paper examines effectiveness of different vaccination strategies. We investigate the effects of two key elements in mass vaccination, which are allocations and timing of first and second doses and types of vaccines, on the spread of COVID-19. Amid limited supply of approved vaccines and constrained medical resources, the choice of a vaccination strategy is fundamentally an economic problem… Expand


Evaluation of COVID-19 vaccination strategies with a delayed second dose
An agent-based model of COVID-19 transmission is developed and shows that for Moderna vaccines with 80% efficacy following the first dose, a delay of 9-12 weeks could enhance the program effectiveness and prevent additional infections, hospitalizations, and deaths, compared to a 4-week interval between the doses. Expand
Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes
It is found that in the short-term, focusing on one dose generally decreases infections, but longer-term outcomes depend on this relative immune robustness, and under certain scenarios, a one-dose policy may increase the potential for antigenic evolution. Expand
Alternative Dose Allocation Strategies to Increase Benefits From Constrained COVID-19 Vaccine Supply
There are important tradeoffs to consider between the health costs of deferring benefits of earlier protection for half of people who could be vaccinated from initial supply, weighed against risks of possible vaccine supply disruptions that could delay receipt of second doses in the absence of sufficient reserves. Expand
Estimating the effectiveness of the Pfizer COVID-19 BNT162b2 vaccine after a single dose. A reanalysis of a study of 'real-world' vaccination outcomes from Israel.
The analysis shows that a single dose of vaccine is highly protective, although it can take up to 21 days to achieve this, and the early results coming from Israel support the UK policy of extending the gap between doses by showing that asingle dose can give a high level of protection. Expand
Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study
A delayed second dose vaccination strategy, at least for people aged under 65, could result in reduced cumulative mortality under certain conditions. Expand
COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study
The findings show the BNT162b2 vaccine can prevent both symptomatic and asymomatic infection in asymptomatic adults and shows effectiveness against adults in the UK. Expand
Anticipation of COVID-19 Vaccines Reduces Social Distancing
We show that the anticipation of COVID-19 vaccines reduces voluntary social distancing. In a large-scale preregistered survey experiment with a representative sample, we study whether providingExpand
Effectiveness of COVID-19 vaccines against variants of concern, Canada
The findings suggest that even a single dose of these 3 vaccine products provide good to excellent protection against symptomatic infection and severe outcomes caused by the 4 currently circulating variants of concern, and that 2 doses are likely to provide even higher protection. Expand
Quantifying the impact of nonpharmaceutical interventions during the COVID-19 outbreak: The case of Sweden
Summary This paper estimates the effect of nonpharmaceutical intervention policies on public health during the COVID-19 outbreak by considering a counterfactual case for Sweden. Using a syntheticExpand
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. Expand